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Summary 
The Bcl6 gene has  been identified from the chromosomal translocation breakpoint in B  cell 
lymphomas, and its products are expressed highly in germinal center (GC) B cells. To investi- 
gate the function of Bcl6 in lymphocytes, we have generated RAGl-deficient mice reconsti- 
tuted with bone marrow cells from Bcl6-deficient mice (Bcl6-/-RM). Lymphogenesis in pri- 
mary lymphoid tissues  of Bcl6-/-RM is normal, and Bcl6-/-RM produced control levels of 
primary IgG1 antibodies specific to T  cell-dependent antigens. However, GCs were not found 
in these mice. This defect was mainly due to the abnormalities of  B cells. Therefore, Bcl6 is es- 
sential for the differentiation of GC B cells. 
C 
hromosomal  translocations involving band  3q27  are 
often present in B  cell lymphomas. The BCL6 gene 
was identified from the breakpoint of these translocations 
(1-3). Rearrangements of the BCL6 gene were detected in 
up to 40% of diffuse large cell lymphomas and 10% of fol- 
licular lymphomas (4,  5).  These rearrangements cause de- 
regulation of the BCL6 gene as a result of the juxtaposition 
of the BCL6 coding region to heterologous promoters (6), 
and its deregulation may be responsible for lymphomagen- 
esis. BCL6 is a 92- to 98-kD nuclear phosphoprotein (7, 8) 
that  contains  six  Kriippel-type  zinc  finger  motifs  in 
COOH-terminal region (1-3, 9), which have been shown 
to bind to specific DNA sequences in vitro (10,  11),  and 
the POZ/BTB  domain  (12,  13)  in NH2-terminal region. 
Because a NH2-terminal half of the protein has been dem- 
onstrated to contain transrepressor  domain(s) in vitro (14--16), 
BCL6  can  function  as  a  sequence-specific transcriptional 
repressor. 
The expression of BCL6 is ubiquitously detected in hu- 
man tissues  (17).  As  this  gene is well conserved between 
human and mouse (9), the expression pattern has been ex- 
tensively studied in mouse tissues. Bcl6 is continuously up- 
regulated in keratinocytes and sperm at their terminal stages 
(18).  Bcl6 expression is also  detected in mature lymphoid 
tissues and transiently upregulated in thymocytes and sple- 
nocytes when  these  cells  were  stimulated  with  chemical 
mediators (PMA plus ionomycin; 9). Furthermore, the ex- 
pression  is  predominant  in  the  germinal  center  (GC) 1 B 
cells of human tonsils, but is undetectable in plasma cells (7, 
8). However, the function of BCL6 in lymphocytes, espe- 
cially in GC B cells, is unknown. 
When mice are immunized with T  cell-dependent anti- 
gens, antigen-reactive B cells in the spleen are activated by 
interaction with CD4 + helper T  cells in periarteriolar lym- 
phoid sheaths (PALS)  (19, 20). These activated B cells gen- 
erate Ab-producing foci in PALS or migrate into follicles to 
form GCs that are identified by their binding capacity to 
peanut agglutinin (PNA). Nascent GC B cells undergo mas- 
sive clonal expansion to form a dark zone occupied by sur- 
face Ig (slg)-negative centroblasts (21,  22). Somatic hyper- 
mutations  of the  Ig  gene  occur in  centroblasts  (23-25). 
These cells  differentiate into  slg-positive  centrocytes at  a 
light zone in GCs. Centrocytes with higher affinity to self- 
antigens  or with lower affinity to immunized antigen un- 
dergo selective apoptosis (26-30),  and those with higher 
1Abbreviations used in this paper: AFC, antibody-fore'ring  cell; AP, alkaline 
phosphatase; Bcl6  -/-, Bcl6-deficient  mice; Bcl6-/-RM, RAGl-deficient 
mice reconstituted with bone marrow cells from Bcl6-deficient  mice; 
BM, bone marrow; BrdU, 5-bromo-2'-deoxyuridine;  CD40L, CD40 
ligand; CG, chicken  ~/globulin; GC, germinal center; GST, glutathione- 
S-transferase; HRP, horseradish peroxidase; NP, 4-hydroxy-3-nitrophenyl 
acetyl; PALS, periarteriolar  lymphoid sheath; PNA, peanut agglutiitin; 
RAG1-/% RAGl-deficient  mice; slg, surface  Ig. 
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forming cells (AFCs) or memory B  cells (31, 32). 
To  investigate the function of Bcl6 in lymphocytes, we 
have  generated  Bcl6-deficient  mice  (Bcl6-/-).  However, 
Bcl6 -/-  displayed growth retardation and mostly died with 
severe  myocardial  injury  by  9  wk  old  CYoshida,  T., 
manuscript  in  preparation).  Therefore,  we  made  tLAG1- 
deficient mice (ILAG1-/-) reconstituted with bone marrow 
(BM)  cells  from  Bcl6  -/-  (Bcl6-/-RM).  As  tLAGl-defi- 
cient lymphocytes cannot develop into a mature form (33), 
all mature lymphocytes developed in Bcl6-/-RM  are  de- 
rived  from  BM  cells  of Bcl6  -/-.  Here,  we  analyzed  the 
function  of lymphocytes  developed  in  Bcl6-/-ILM.  Al- 
though  mature  lymphocytes  were  developed  in  spleen 
from  Bcl6-/-RM,  GC  formation  was  impaired  in  the 
spleen. We discuss the possible function of  Bcl6 in GC B cells. 
Materials  and Methods 
Animals.  C57BL/6 mice were purchased from Japan SLC Co. 
Ltd. (Hamamatsu, Japan). Bcl6  -/- (Yoshida, T., manuscript in prep- 
aration) and 1LAG1-/- (33) were described in detail previously. 
mAbs and Flow Cytometry.  mAbs used for cell surface staining 
were FITC-anti-B220 (tLA3-6B2;  PharMingen, San Diego, CA), 
-anti-CD8  (Ly-2;  PharMingen),  biotinylated anti-IgM  (II/41; 
PharMingen),  PE-anti-CD4  (L3T4;  PharMingen),  and-anti- 
CD3e  (145-2Cll;  PharMingen).  For flow  cytometric analysis, 
cells were stained with antibodies for 30 rain on ice. The cells were 
further  incubated with  a  PE-streptavidin  (PharMingen)  for  15 
min  on  ice. The  stained cells were  analyzed by FACSCalibur  ~ 
(Becton Dickinson, San Jose, CA). 
Generation of Bcl6-/-RM.  tLAG1  -/-  (8-16  wk  old)  were 
sublethally irradiated (3.5  Gy) and injected with 2-5  X  106 BM 
cells from Bcl6  -/- or Bcl6  +/+  littermates (3-5 wk old). The re- 
constitutions were  confirmed 8-12  wk  after transplantation by 
identifying CD3 + and B220 + mature lymphocytes in peripheral 
blood from Bcl6+/+RM and Bcl6-/-R.M with flow cytometry. 
Immunization.  DNP-OVA  was  prepared  by  coupling  of 
OVA  (Sigma Chemical Co.,  St.  Louis,  MO)  with  2,4-dinitro- 
phenylbenzensulfonic acid under  alkaline  condition  (34).  NP- 
chicken ",/globulin (NP-CG) was made by reaction of succinirnide 
ester of 4-hydroxy-3-nitrophenyl acetyl (NP;  Genosys Biotech- 
nology, Inc., Woodlands, TX)  and CG  (Sigma Chemical Co.). 
Mice were  immunized intraperitoneally with  100  Ixg of alum- 
precipitated DNP-OVA  or NP-CG.  Sera were  collected from 
the mice 7 d  (for IgM) and 14 d  (for IgG1) after immunization. 
Figure 1.  Bcl6  expression in spleen fi:om  immunized C57BL/6. Spleen sections fi'om C57BL/6 mice on day 14 (A and B) or day 7 (C and D) after im- 
munization were stained with anti-Bcl6 Ab (A and B) or anti-Bcl6 and anti-k light chain Abs (C and D). Brown signals  in nuclei and membranous blue 
signals indicate Bcl6 protein and k light chain, respectively. Sections were counterstained with hematoxylin (/t and B). Arrows and arrowheads indicate 
centroblasts  and centrocytes respectively. 
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Figure  2.  Normal development of B and T cells in Bcl6-/-RM. Rep- 
resentative flow cytometric analysis of BM cells (A), thymocytes (B), and 
splenocytes (C and D)  from  Bcl6+/+RM  (left column) and Bcl6-/-RM 
(right column).  Numbers indicate  relative  percentages  of positive  cells 
within a quadrant• 
Amounts  of DNP-specific  Abs  in  the  sera  were  measured  by 
ELISA as described previously (34). 
Immunohistochemistry.  A  SmaI-XhoI  fragment  of  murine 
Bd6  cDNA  (mBcl6SX)  was  inserted  into  pGEX4T-2  vector 
(Pharmacia Biotech, Piscataway, NJ).  The resulting glutathione- 
S-transferase (GST)-mBcl6SX fusion protein was used to immu- 
nize rabbits to raise  anti-Bcl6 antibodies. The immune sera were 
precleared by passage  through  GST-Sepharose columns and af- 
finity purified with antigen columns on which  GST-mBcl6SX 
protein was coupled to activated CH Sepharose (Pharmacia Bio- 
tech). 
Spleens were isolated from C57BL/6, Bcl6-/-RM, or Bcl6 +/+ 
RM after immunization, one third were used for flow cytometric 
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Control levels of primary  Abs  in  sera from  immunized 
Bcl6-/-RM. Bcl6-/-RM (closed circles) and Bcl6+/+RM (open dr&s) were 
immunized with DNP-OVA. IgM and IgG1 anti-DNP titers in the sera 
were measured by ELISA. 
analysis, and two  thirds were  embedded in O.C.T.  compound 
(Miles, Incorporated, Elkhart, IN) and frozen in liquid nitrogen. 
Serial frozen sections (6 ~m) were fixed in cold acetone and the 
activity of endogeneous peroxidase was quenched with 3% H202 
in methanol. Sections were stained with anti-Bcl6 Ab, PNA cou- 
pled to horseradish peroxidase (HR.P) (EY Laboratories, San Ma- 
teo,  CA),  biotinylated anti-B220 Ab  (PharMingen), or alkaline 
phosphatase  (AP)-labeled goat anti-mouse k light chain Ab (South- 
em Biotechnology Associates, Inc., Birmingham, AL) as the first 
reagents. A biotinylated goat anti-rabbit antibody (Nichirei, To- 
kyo,  Japan)  and  streptABComplex-HRP  (Dako,  Carpinteria, 
CA) were used as the second- and third-phase reagents, respec- 
tively. Bound HI<P and AP activities were visualized with the di- 
aminobenzidine detection kit  (DAB  kit;  Nichirei)  and the  fast 
blue kit (Nichirei), respectively. 
Preparation  of Splenic B  and T  Cells.  Splenic B  cells  were  en- 
riched by depleting non-B lineage cells from spleen cells. In brief, 
spleen cells were incubated with mixture ofbiotinylated mAbs to 
CD3, CD4, CD8, TER119 (PharMingen), and CD11b (Mac-l) 
(M1/70;  PharMingen).  These  cells  were  subsequently reacted 
with streptavidin-coated immunomagnetic beads  (BioMag;  Per- 
Septive  Diagnostics,  Cambridge,  MA).  Labeled  cells  were  re- 
moved by applying them in a magnetic field. The resulting B cell 
fraction contained >95%  of B220 +  cells and <0.5%  of CD3 + 
cells. Splenic T  cells were also enriched by a similar manner with 
mAbs to B220, TER119, and Mac-1. Resulting T  cells contained 
<0.5%  of B220 + cells.  The mixture of separated B  and T  cells 
(107 cells  each) were injected intravenously into RAG1 -/-. The 
mice were immunized with DNP-OVA 1 d after transplantation. 
Spleens were isolated on day 14 after immunization. 
BrdUIncorporation  Assay.  Proliferating  cells  in  spleen  were 
histologically detected by 5-bromo-2'-deoxyuridine (BrdU) in- 
corporation assay (31).  BrdU (2 mg; Boehringer Mannheim, In- 
dianapolis, IN)  was injected intraperitoneally in Bcl6-/-RM  or 
441  Fukuda et al. Figure 4.  GC formation  is impaired in spleen from Bcl6-/-RM. Splenocytes from Bcl6+/+RAVI  (A) and BcI6-/-RM (B) immunized with DNP--OVA 
on day 14 after immunization were stained with PNA and anti-B220 Ab. The numbers in the figures indicate percentages of PNA  high B220 + cells relative 
to total B220 + cells. Splenic sections from the immunized Bcl6+/+RM (C and E) and Bcl6-/-RM (D and F) were stained with PNA (C and D) or anti- 
B220 Ab (E and F) (brown). Hematoxylin counterstain.  G, germinal center; T, T cell-rich PALS; M, marginal zone; F, primary follicle. 
Bd6+/+RM on day 3 after immunization with DNP-OVA. Spleens 
were isolated 2  h  after BrdU injection and their sections were 
incubated  with  PNA-HtLP  for  identifying  GC  B  cells.  After 
color development with DAB, the sections were incubated in 2N 
HC1 at 37°C for 1 h, and then reacted with mouse mAb to BrdU 
(Boehringer Mannheim). The sections were further incubated with 
biotinylated rabbit  anti-mouse  Ig Ab  (Dako),  followed by stain- 
ing with streptABComplex-AP (Dako). The fast blue kit (Nichirei) 
was used for chromogen.  Therefore, blue color staining indicates 
both BrdU uptake in nuclei and Ig on B  cells. 
Proliferation Assay.  Splenic B cells (5  ×  104/well) from Bcl6  -/- 
RM  were cultured with LPS  (10  p.g/ml; Sigma Chemical Co.), 
IL-4 (102 U/ml; culture supernatant  of X63Ag8-653  cells trans- 
fected with murine  IL-4 gene; reference 35),  goat anti-IgM Ab 
(anti-w;  10 ~g/ml; Jackson ImmunoResearch Laboratories, West 
Grove, PA), or CD40 ligand (CD40L)-transfected Chinese ham- 
ster ovary cells (a gift from H. Yagita, Juntendo  University, To- 
kyo, Japan;  2  ×  104  cells fixed with paraformaldehyde  per well) 
in  96-well flat-bottomed rnicroplates for 48  h.  The  cultures were 
pulsed with 1 ~Ci of [3H]thymidine  (Amersham International, Ay- 
442  Bcl6 in Germinal Center Formation lesbury, UK) for 6 h, and [3H]thymidine uptake was measured in a 
scintillation counter. 
Results 
Bcl6 Is Strongly Detected in GC, but Not in PALS-associated 
Foci.  We  have  made  polyclonal  antibodies  specific  for 
mouse Bcl6 and immunohistologically analyzed the expres- 
sion in GCs from spleens of immunized mice. The GC re- 
action in  spleen reaches  its maximum by days  10-12  and 
keeps the same high levels until day 21  after immunization 
(31,  36).  Therefore,  expression  of Bcl6  was  examined  in 
spleens of normal C57BL/6 mice immunized with T  cell- 
dependent antigen,  DNP-OVA,  on day 14 after immuni- 
zation (Fig.  1, A  and B). Bcl6 was detected strongly in nu- 
clei  of most of GC B  cells  and weakly in  those  of other 
lymphocytes in white pulps. 
After activation by helper T  cells in PALS, antigen-reac- 
tive B  cells  migrate into follicles to form GCs or generate 
Ab-producing foci in PALS. The PALS-associated foci can 
be  identified  by  immunohistological  staining  of  spleens 
from  C57BL/6  mice  immunized  with  an  immunogenic 
conjugate of NP with anti-h light chain antibody (36).  The 
peak of the  focus formation occurs on about day  10 after 
immunization (36).  Thus, Bcl6 expression in PALS-associ- 
ated foci from the mice immunized with NP-CG was ana- 
lyzed on day 7  after immunization.  Although  strong Bcl6 
expression was detected in GCs, it was not detected in the 
PALS-associated foci (Fig.  1,  C  and D). Anti-h light chain 
antibody used in this staining also distinguished centroblasts 
(slg-)  from centrocytes  (slg  +)  in  GCs,  in  both  of which 
Bcl6 expression was strongly upregulated. 
Germinal  Center  Formation  Is  Impaired  in  Bd6-/-RM. 
Since Bcl6 -/-  mostly died  at young age,  the  function  of 
Bcl6  in  lymphocyte  development  was  investigated  in 
R_AG1 -/-  reconstituted  with  BM  cells  from  Bcl6  -/- 
(Bcl6-/-RM).  Flow  cytometric  analysis  of BM  cells  and 
thymocytes from Bcl6-/-RM  3  mo  after  transplantation 
revealed no abnormality in early lymphocyte development 
(Fig.  2, A  and B). Percentages of B220 + B  cells,  CD4 +, or 
CD8 +  T  cells  in  spleens from the  Bcl6-/-R.M  were  also 
comparable to those from Bcl6+/+ILM  (Fig.  2,  C  and D). 
Although  Bcl6 expression can be detected in  murine BM 
cells,  thymocytes, and  splenocytes  (9),  these  data indicate 
that Bcl6 is not essential for lymphogenesis in primary lym- 
phoid tissues. 
We  then  analyzed the  function  of mature lymphocytes 
in  Bcl6-/-RM  by  immunizing  them  with  DNP-OVA. 
Titers  of primary  IgM  and  IgG1  anti-DNP  Abs  in  sera 
from the mice on day 7  (IgM) and on day 14 (IgG1) after 
immunization were measured by ELISA. Bcl6-/-RM pro- 
duced the primary IgM Abs and IgG1 Abs at levels compa- 
rable to  those  of Bcl6+/+RM  (Fig.  3).  These results indi- 
cate that Bcl6 is not essential for differentiation of mature B 
cells into IgGl-producing plasma cells. 
GC  formation  was  histologically  analyzed  in  spleens 
from mice  immunized  with  DNP-OVA  on  day  14  after 
immunization. PNA-binding GC B  cells were clearly iden- 
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Figure  S.  PALS-associated  focus formation is not impaired in spleen 
from Bcl6-/-RM. Splenic sections from Bcl6+/+RM (A) and Bcl6-/-RM 
(/3) immunized with NP-CG on day 7 after immunization were stained 
with and-k light chain Abs (blue) and PNA (brown). 
tried in all of the Bcl6+/+RM analyzed (n  =  8,  Fig.  4, A 
and  C).  In contrast, none of the Bcl6-/-RM spleens (n  = 
8)  showed PNA-binding B  cells  in follicles (Fig.  4,  B  and 
D),  although primary B  cell follicles, marginal zones,  and 
PALS were histologically identified (Fig.  4 F). 
Because the  great majority of Abs produced in the  first 
12 d  after immunization are derived from PALS-associated 
foci  (37),  the  focus formation in  PALS  was histologically 
analyzed  in  spleens  from  Bcl6-/-RM  immunized  with 
NP-CG on day 7 after immunization with anti-k light chain 
antibody. PALS-associated foci and PNA-binding GCs could 
be detected in the Bcl6+/+RM (Fig.  5 A). Although PNA- 
binding GCs were absent in the Bcl6-/-RM, PALS-associ- 
ated foci could be identified  (Fig.  5  B).  Therefore, Bcl6 is 
essential for GC formation in follicle but not for focus for- 
mation in PALS. 
Bcl6 Is Required  in  B,  but  Not in  T  Cells for  GC Forma- 
tion.  Functions of T  cells in GCs are essential for GC for- 
mation of B  cells  (38,  39) and BCL6 is detected in a small 
fraction of CD4 + T  cells in GCs (7). To determine whether 
defects in GC formation in Bcl6-/-RM are due to defects 
in B  or T  cells or both, splenic T  and B  cells were isolated 
from Bcl6-/-RNI and Bcl6+/+RM and then co-transferred 
into RAG1-/-  1 d before immunization with DNP-OVA. 
GC formation in the spleen was histologically analyzed 2 wk 
later.  GC formation was detected in spleens from mice re- 
constituted with B  cells from Bcl6+/+RM and T  cells from 
Bcl6-/-R.M  (Fig.  6  A).  In contrast,  co-transfer of B  cells Figure 6.  B cells are responsi- 
ble for the defect of GC forma- 
tion in Bcl6  -/- RM. Spleen sec- 
tions  from  the  DNP-OVA 
immunized RAG1  -/-  reconsti- 
tuted with B cells from Bcl6  +/+ 
RM  and T  cells from Bcl6  -/- 
RM  (A), or with  B  cells from 
Bcl6-/-R.M  and  T  cells from 
Bcl6+/+RM  (B)  were  stained 
with PNA (brown). Hematoxy- 
lin counterstain. 
from Bcl6-/-RM  and T  cells from Bcl6+/+RM did not re- 
store GC formation (Fig. 6 B), indicating that Bcl6 expres- 
sion in B  but not in T  cells  is essential for the GC forma- 
tion. 
Nascent  GC  Formation  Is  Absent  in  Spleen from  Bcl6  -/- 
RM.  GC first appears in splenic follicles by day 4 and be- 
gins to wane by day 21  after immunization  (31).  It might 
be possible that GC formation occurs in Bcl6-/-RM shortly 
after immunization but cannot be maintained.  To examine 
the possibility,  the presence of PNA-binding GCs was ex- 
amined in spleens from Bcl6-/-RM immunized with DNP- 
OVA at an early stage after immunization.  Nascent PNA- 
binding GCs could be identified in the Bcl6÷/+RM spleen 
on day 3  after immunization  (Fig.  7  A)  and Bcl6 was de- 
tected strongly in nuclei of  these GC B cells (data not shown). 
However,  the nascent  GCs were not detected at all in the 
Bcl6-/-RM on day 3  (Fig. 7 B) and day 4 (data not shown) 
after immunization. 
To exclude the possibility that nascent GC B  cells from 
Bcl6-/-P,.M  cannot obtain the PNA-binding capacity, the 
presence of  blast cells in S phase in splenic follicles from the 
Bcl6-/-RM  on day 3 after immunization was histologically 
analyzed using BrdU incorporation  assay,  because  nascent 
GC  B  cells  undergo  massive  clonal  expansion  in  follicles 
(21,  22).  About  half the  numbers  of GC  cells  in  spleen 
from the Bcl6+/+RM  were positive for BrdU  uptake  2  h 
after  pulse  (Fig.  7  A).  However,  no  BrdU-positive  cells 
were  detected  in  B  cell  follicles  from  the  Bcl6-/-RM 
spleen  (Fig.  7  B),  suggesting  that  antigen-reactive  B  cells 
activated by helper T  cells  in PALS cannot proliferate at all 
in splenic follicles. 
We then examined the capacity for proliferation of ma- 
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Figure  7.  Nascent  GC  is absent in spleen from Bcl6-/-RM.  Spleen 
sections from BcI6+/+RM (A) and Bcl6-/-RM (B) on day 3 after immu- 
nization were stained with anti-BrdU Ab and PNA. Strong blue signals in 
the nuclei and membranous weak blue signals indicate BrdU uptake and 
cell surface lgs, respectively. Brown signals in follicle of  Bcl6+/+RM indi- 
cate PNA-reactive GC cells. 
ture B cells from Bcl6-/-RM in vitro. Splenic B cells from 
Bcl6-/-RM were stimulated with LPS, LPS plus IL-4, anti- 
IgM Ab, CD40L, or anti-IgM plus CD40L. DNA synthesis 
of these stimulated cells was analyzed on day 2 after stimu- 
lation.  Splenic B  cells  from Bcl6-/-RM proliferated well 
against  these stimuli similar to those from Bcl6+/+tkM (Fig. 
8).  Therefore, antigen-reactive B  cells in Bcl6-/-RM may 
have a  capacity to proliferate by antigen stimulations  and 
signals from helper T  cells in PALS. 
Discussion 
Antigen-reactive B  cells  activated by helper  T  cells  in 
PALS  further differentiate into  AFCs  in  PALS  or  GC  B 
cells in follicles.  We show here that Bcl6 is essential  for dif- 
ferentiation of GC B  cells  (Fig.  4).  However, Bcl6 is not 
required for the focus formation in PALS by antigen-reac- 
tive B  cells  (Fig.  5).  This is also supported by the evidence 
that Bcl6 expression is not upregulated in PALS-associated 
loci  (Fig.  1).  Because primary AFCs  and  GC B  cells  are 
thought to be derived from a common clonal origin (40), 
Bcl6 may be an essential transcription factor for the differen- 
tiation pathway into GC B  cells. Although it is still argued 
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Figure  8.  Proliferation  capacity of splenic B  cells from Bcl6-/-RM. 
Proliferative  responses of splenic B  cells  from Bcl6+/+RM  (shaded bars) 
and Bcl6-/-RM (closed bars) to indicated stimuli. Results represent means 
and variations (SD) from triplicate cultures. The data presented are repre- 
sentative of three independent experiments. 
that these cells originate from distinct cell lineages (41, 42), 
Bcl6 is a regulator for the differentiation of GC B cells. 
Bcl6 expression is upregulated in nascent GC B cells (data 
not shown)  and detected in both centroblasts and centro- 
cytes in GCs from normal mice (Fig.  1). Furthermore, GC 
formation is impaired in Bcl6-/-RM  (Fig.  4).  Therefore, 
signals  that upregulate Bcl6 expression in antigen-reactive 
B  cells  are  essential for the differentiation of GC B  cells. 
Stimulation of mature B  cells with CD40L plus anti-IgM 
Ab induces phenotypic markers on GC B cells (43), and LPS 
plus IL-4 induces RAG1 and RAG2 expression (44) and Ig 
isotype class-switching  in B cells like GC B cells (45). How- 
ever, these  signals  cannot make  upregulation  of Bcl6 ex- 
pression in mature B  cells  (data  not shown;  reference 46). 
Interactions of antigen-reactive B cells with helper T  cells in 
PALS through cell surface molecules such as CD40-CD40L 
and CD86(B7-2)-CD28 are required for the differentiation 
(47-51). Because the blocking of these interactions inhibits 
both  primary Abs  production  and  GC  formation,  signals 
from these interactions may be required for both differenti- 
ation pathways. Follicular dendritic cells are unique cells in 
follicles  (19).  Helper T  cells in GCs have also unique char- 
acters that are distinct from those of helper T  cells in PALS 
(52, 53). These cells seem to be required for GC formation 
by antigen-reactive B  cells. Interactions of the B  cells with 
these dendritic cells or GC-helper T  cells may be a possible 
origin of the signals that upregulate Bcl6. Further study on 
the signals will be able to elucidate the molecular mecha- 
nism of differentiation into GC B cells. GC  formation  is  also  impaired  in  mice  lacking  genes 
other  than  Bcl6.  Lymphotoxin-c~-  (54)  or  TNF-ot-defi- 
cient  mice  (55)  can  produce  primary  IgG1  Abs  without 
GC formation like Bcl6-/-RM.  The defect in GC forma- 
tion may be due to the abnormality ofmicroarchitecture of 
spleens  (56). Chemokine receptor, Blrl-deficient mice also 
produce normal levels of primary IgGl Abs without func- 
tional  GCs  (57).  Although  PNA-binding B  cells  are  de- 
tected in PALS from the Blrl-deficient mice after immuni- 
zation,  these B  cells  fail  to migrate from PALS into B  cell 
follicles  in  the  spleen.  However,  mature  B  cells  from 
Bcl6-/-RM  can migrate into follicles to form the  normal 
microarchitecture of spleens (Fig. 4 F). Mice lacking CD40 
(47,  48),  complement receptors  (C1L1  and CR2)  (58,  59), 
or CD28  (51)  display impairments  of both  GC formation 
and primary IgG1 production to T  cell-depedent antigens, 
but  BcI6-/-RM  produced  normal  levels  of the  primary 
IgG1 Abs (Fig. 3). Therefore, the mechanism of the defect 
in GC formation in Bcl6-/-RM is distinct from the mech- 
anisms in these deficient mice. 
There  are two  distinct  types of B  cells in  GCs:  centro- 
blasts  and  centrocytes.  Several  unique  molecular  events 
such  as  somatic  hypermutation  of the  Ig gene,  Ig isotype 
class-switching, selective cell death, and differentiation into 
memory B  cells occur separately in each type of GC B cells 
(60).  Bcl6  expression  is  continuously upregulated  in both 
types ofGC B cells (Fig. 1), suggesting that Bcl6 is required 
not for each specific molecular event in GC B  cells  but for 
more fundamental events throughout GC reactions.  These 
events may not be related with proliferation of GC B  cells 
because Bcl6 is strongly detected in both cell  cycling cen- 
troblasts and resting centrocytes (Fig.  1) and splenic B  cells 
lacking Bcl6 can proliferate to various stimuli (Fig. 8). 
BCL6 was identified  as an oncogene involved in chro- 
mosomal rearrangements in B  cell lymphoma. Bcl6 expres- 
sion is  ubiquitous  in  mature  tissues  and  is  upregulated  in 
cardiac myocytes, keratinocytes,  and sperm at their termi- 
nal stages. Furthermore, Bcl6-deficient mice die'with spon- 
taneous death  of mature  cardiac myocytes, suggesting that 
mature heart muscle without Bcl6 cannot maintain its dif- 
ferentiation stage. Although the GC stage is not a terminal 
stage of B cell differentiation, Bcl6 is continuously upregu- 
lated in GC B  cells (Fig.  1).  If the specific function of Bcl6 
is shared between B  cells at the GC stage and heart muscle 
at the  terminal  stage, Bcl6 may be essential  for protection 
of the  GC B  cells  against  specific  stresses  such  as  somatic 
hypermutation  and  selective  cell  death.  Furthermore,  this 
protective function may also contribute to lymphomagene- 
sis ofGC B  cells by deregulation of BCL6. 
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